Annovis Bio, Inc. (ANVS) · Nov 4, 2026 · Other events

Annovis cash warning: $2.8M left before Phase 3 readout

Cash warning — Preliminary cash ~$2.8M vs $18.7M at June 30

Annovis’ preliminary cash update shows $2.8M remaining after a sharp quarterly drawdown, raising funding pressure ahead of its Phase 3 Alzheimer’s readout.

Annovis is a Phase 3 biotech racing buntanetap toward a planned early-2027 Alzheimer’s data readout and potential NDA path; its pivotal trial is fully enrolled with 850 patients, while a Parkinson’s extension study is still enrolling. The immediate problem is liquidity, not clinical execution. Annovis estimates only about $2.8 million of cash and cash equivalents remained on September 30, down from $18.7 million just three months earlier. The company explicitly says its quarterly financial statements are not yet complete and the figure is unaudited and subject to change.

September 30, 2026June 30, 2026
Cash and cash equivalents (preliminary)$2.8M (-85.0%)$18.7M

That balance is materially worse than the company’s prior funding setup implied. At June 30, Annovis already disclosed that its $18.7 million cash balance was insufficient to fund operations for twelve months, while its program was moving toward the 2027 data milestone. The new estimate indicates that roughly $15.9 million was consumed in one quarter, before the company has reported the full quarter’s expenses or cash-flow statement.

The filing raises a near-term financing risk around the core catalyst. Annovis previously raised capital while presenting its financing as extending the runway toward the Phase 3 Alzheimer’s program and its six-month NDA submission path. With only approximately $2.8 million preliminarily on hand, the company appears unlikely to reach the next major clinical milestone without additional capital, a sharp spending reduction, or another funding source. That is an inference from the disclosed cash decline and the company’s existing operating needs, not a financing announcement in this filing.

The clinical story itself is unchanged, but the ability to fund it is now the dominant issue. The filing contains no new efficacy, safety, enrollment, or regulatory information; it is a preliminary cash disclosure. 〔0〕 Bottom line: This does not damage buntanetap’s clinical thesis directly, but it sharply weakens the company’s financial position ahead of its most important readout. The funding overhang is new and substantial, making this a clearly negative business update rather than routine quarterly housekeeping.

What to watch next

Q3 financial statements and any financing announcement

Original filing on SEC EDGAR

More Annovis Bio, Inc. news

Annovis cash warning: $2.8M left before Phase 3 readout | ANVS Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.